Investment Banking
Kevin Eisele, managing director on William Blair’s equity capital markets team, joined the Wall Street Journal’s Venture Capital Pro Newsletter team to discuss how venture capital fundraising growth for biotech companies has exceeded 2023’s first quarter.
While the fundraising numbers are pointing in the right direction, Eisele noted that there’s still “caution” in the market.
Stay up-to-date with the latest William Blair news and insights
William Blair acted as the exclusive financial advisor to Clio in connection with its $900 million Series F investment round led by New Enterprise Associates, at a $3.0 billion valuation.
Read morePrivate capital markets have remained extremely active in recent years as company leaders and financial sponsors seek to utilize flexible, non-control capital solutions to generate partial liquidity, accelerate organic and inorganic growth, and optimize their balance sheets.
Read moreWilliam Blair served as exclusive financial advisor to KKR in connection with its acquisition of a majority stake in Agiloft, a portfolio company of FTV Capital (FTV).
Read moreInformation contained on the internet is not subject to William Blair & Company's control or review, and may not be accurate.
For disclosure information, please visit www.williamblair.com/disclosures
